SecurityGALE / Galena Biopharma, Inc. (363256108)
President and CEOStergiou Andelos M.
IndustryPharmaceutical Preparations
Institutional Owners8
Institutional Shares1,193,283 - 17.93%
Common Shares Outstanding6,655,155 shares (as of 2018-03-31)
Institutional Value$ 1,196,000 USD
Related GALPW / Galena Biopharma, Inc. Warrants exp. 2017-12-21
GALEW / Galena Biopharma, Inc. Warrants exp. 2018-09-18

Institutional Stock Ownership and Shareholders

GALE / Galena Biopharma, Inc. Institutional Ownership

Galena Biopharma, Inc. (NASDAQ:GALE) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,193,283 shares. Largest shareholders include CVI Investments, Inc., BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, Spot Trading L.l.c., Spot Trading L.L.C, BlackRock Advisors LLC, Spot Trading L.l.c., Spot Trading L.L.C, and MetLife Securities, Inc.
Galena Biopharma, Inc. (NASDAQ:GALE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/gale"><img src="https://images.fintel.io/us-gale-so.png" alt="GALE / Galena Biopharma, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-01-13 13F-HR MetLife Securities, Inc 54 0
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 23,900 0 -100.00 6 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 3,160,286 0 -100.00 828 0 -100.00
2018-05-15 13F-HR CREDIT SUISSE AG/ 20,041 0 -100.00 5 0 -100.00
2018-04-20 13F-HR Steward Partners Investment Advisory, Llc 1,125 0 -100.00 0 0
2018-05-14 13F-HR Icon Wealth Partners, Llc 550 0 -100.00 0 0
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 55 0 -100.00 0 0
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 169,500 0 -100.00 44 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 23,360 0 -100.00 6 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 6,014,689 351,882 -94.15 2,107 683 -67.58
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 17,253 0 -100.00 5 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 2,005 0 -100.00 1 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 12,000 0 -100.00 3 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 84 0 -100.00 0 0
2017-07-27 13F-HR Spot Trading L.l.c. Put 7,500 4
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 18,428 0 -100.00 5 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 3 0 -100.00 0 0
2018-05-15 13F-HR/A Sabby Management, LLC 2,623,610 0 -100.00 687 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 4,398,909 0 -100.00 1,541 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 708,015 36,205 -94.89 248 70 -71.77
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 18,822 0 -100.00 5 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 37,420 0 -100.00 10 0 -100.00
2017-05-01 13F-HR Spot Trading L.L.C Call 13,100 0 -100.00 25 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC Call 88,800 0 -100.00 23 0 -100.00
2017-05-01 13F-HR Spot Trading L.L.C Put 0 7,500 0 5
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,027 0 -100.00 0 0
2017-07-27 13F-HR Spot Trading L.l.c. 5,000 3
2018-04-18 13F-HR Integral Derivatives, LLC Call 18,200 0 -100.00 5 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 106,061 0 -100.00 37 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 50 0 -100.00 0 0
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 630 0 -100.00 1 0 -100.00
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 37,047 0 -100.00 10 0 -100.00
2018-05-10 13F-HR Winfield Associates, Inc. 3,000 0 -100.00 1 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 23,582 0 -100.00 6 0 -100.00
2017-02-10 SC 13G/A CVI Investments, Inc. 14,000,000 569,901 -95.93
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Put 26,300 0 -100.00 7 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 133,454 0 -100.00 35 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 0 219,939 0 427
2018-05-15 13F-HR UBS Group AG 24,881 0 -100.00 7 0 -100.00
2017-08-08 13F-HR Airain ltd 86,248 0 -100.00 53 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 5,302 10
2017-05-08 13F-HR ARXIS SECURITIES LLC 13,039 0 -100.00 25 0 -100.00
2018-05-15 13F-HR STATE STREET CORP 114,356 0 -100.00 30 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 39,200 0 -100.00 10 0 -100.00
2018-05-03 13F-HR Crescent Grove Advisors, Llc 120,000 0 -100.00 31 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 66,795 0 -100.00 18 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 919,626 0 -100.00 241 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 39,865 0 -100.00 10 0 -100.00
2018-05-15 13F-HR/A Sabby Management, LLC Call 7,602 0 -100.00 199 0 -100.00
2018-05-15 13F-HR Advisor Group, Inc. 202 0 -100.00 0 0
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 111,705 0 -100.00 29 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 36,205 0 -100.00 70 0 -100.00
2018-05-15 13F-HR Alyeska Investment Group, L.P. Call 70,735 0 -100.00 556 0 -100.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 16,983 0 -100.00 4 0 -100.00
2017-01-13 13F-HR MetLife Securities, Inc 1,090 0 -100.00 0 0
2017-05-01 13F-HR Spot Trading L.L.C 17 5,000 29,311.76 0 3
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 892,100 0 -100.00 234 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 50,929 0 -100.00 13 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 3 0 -100.00 1 0 -100.00
GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Nete: Convicted Embezzler, Promotional Investor Relations Firm and more

2018-05-10 valuewalk
As our previous article indicated, we can only wonder why Net Element Inc. (NETE) would use MissionIR as its investor relations firm. After all MissionIR was recently fined and subject to a Cease and Desist order from the SEC. The SEC also said MissionIR “operated as a fraud upon investors and violated, and caused violations of, the anti-touting provisions of the federal securities law.” If I were the CEO of a public company, I’m not sure that is the kind of IR firm I would want representing me. (64-0)

More Red Flags For CNBC's Jon Najarian And Net Element Nete

2018-05-09 valuewalk
Its been a week since we publicly raised questions about why Jon Najarian of CNBC had not filed any Form 4s relating to shares he claimed to have purchased in Net Element Inc. (NETE). It remains unclear to us why he still has not filed these forms as required by the SEC, but the more time that passes the more we are inclined to believe that he never actually purchased the shares. (352-1)

The pain hustlers insys therapeutics paid millions to doctors

2018-05-04 cnbc
Selling drugs is a relationship business. It's best to do it in person. That is why, on a summer evening in 2012, Alec Burlakoff was out for dinner with Steven Chun, the owner of Sarasota Pain Associates. Burlakoff was a sales manager for Insys Therapeutics, an Arizona-based pharmaceutical company with only one branded product, a new and highly potent opioid painkiller called Subsys. Chun was a doctor who prescribed a lot of opioids. (16-0)

The Opioid that Made a Fortune for Its Maker — and for Its Prescribers - The New York Times

2018-05-04 nytimes
Insys Therapeutics paid millions of dollars to doctors. The company called it a “speaker program,” but prosecutors now call it something else: a kickback scheme. (16-0)

CUSIP: 363256108